Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 569

1.

Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials.

Khan A, Schwartz K, Stern C, Redding N, Kolts RL, Brown WA, Robinson DS.

J Clin Psychiatry. 2007 Dec;68(12):1828-33.

PMID:
18162012
[PubMed - indexed for MEDLINE]
2.

The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia.

Isaac M, Koch A.

Eur Neuropsychopharmacol. 2010 Mar;20(3):139-45. doi: 10.1016/j.euroneuro.2009.12.002. Epub 2010 Jan 6.

PMID:
20053539
[PubMed - indexed for MEDLINE]
3.

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.

Schneider LS, Dagerman KS, Insel P.

JAMA. 2005 Oct 19;294(15):1934-43.

PMID:
16234500
[PubMed - indexed for MEDLINE]
4.

Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics.

Finkel S, Kozma C, Long S, Greenspan A, Mahmoud R, Baser O, Engelhart L.

Int Psychogeriatr. 2005 Dec;17(4):617-29. Epub 2005 Oct 5.

PMID:
16202186
[PubMed - indexed for MEDLINE]
5.

Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/hyperactivity disorder participating in psychopharmacology clinical trials.

Khan A, Faucett J, Morrison S, Brown WA.

JAMA Psychiatry. 2013 Oct;70(10):1091-9. doi: 10.1001/jamapsychiatry.2013.149.

PMID:
23986353
[PubMed - indexed for MEDLINE]
6.

Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database.

Khan A, Khan SR, Leventhal RM, Brown WA.

Am J Psychiatry. 2001 Sep;158(9):1449-54.

PMID:
11532730
[PubMed - indexed for MEDLINE]
7.

Review of the efficacy of placebo in comparative clinical trials between typical and atypical antipsychotics.

Oliveira IR, Nunes PM, Coutinho DM, Sena EP.

Rev Bras Psiquiatr. 2009 Mar;31(1):52-6. Review.

PMID:
19506777
[PubMed - indexed for MEDLINE]
Free Article
8.

Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature.

Jeste DV, Dolder CR, Nayak GV, Salzman C.

Harv Rev Psychiatry. 2005 Nov-Dec;13(6):340-51. Review.

PMID:
16373328
[PubMed - indexed for MEDLINE]
9.

Selection of atypical antipsychotics for the management of schizophrenia.

Sprague DA, Loewen PS, Raymond CB.

Ann Pharmacother. 2004 Feb;38(2):313-9. Epub 2003 Dec 30. Review.

PMID:
14742771
[PubMed - indexed for MEDLINE]
10.

Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.

Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW.

Arch Gen Psychiatry. 2005 Dec;62(12):1305-12.

PMID:
16330718
[PubMed - indexed for MEDLINE]
11.

A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementia.

Kryzhanovskaya LA, Jeste DV, Young CA, Polzer JP, Roddy TE, Jansen JF, Carlson JL, Cavazzoni PA.

J Clin Psychiatry. 2006 Jun;67(6):933-45.

PMID:
16848653
[PubMed - indexed for MEDLINE]
12.

Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study.

Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, Lublin H, Fink-Jensen A, Lindhardt A, Mortensen PB.

J Clin Psychiatry. 2010 Feb;71(2):103-8. doi: 10.4088/JCP.08m04818yel. Epub 2009 Nov 3.

PMID:
19895781
[PubMed - indexed for MEDLINE]
13.

Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients.

Aparasu RR, Jano E, Johnson ML, Chen H.

Am J Geriatr Pharmacother. 2008 Oct;6(4):198-204. doi: 10.1016/j.amjopharm.2008.10.003.

PMID:
19028375
[PubMed - indexed for MEDLINE]
14.

Comparison of the efficacy and acceptability of atypical antipsychotic drugs: a meta-analysis of randomized, placebo-controlled trials.

Srisurapanont M, Maneeton N.

J Med Assoc Thai. 1999 Apr;82(4):341-6.

PMID:
10410494
[PubMed - indexed for MEDLINE]
15.

Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia.

Lambert BL, Chang KY, Tafesse E, Carson W.

J Clin Psychopharmacol. 2005 Feb;25(1):12-8.

PMID:
15643095
[PubMed - indexed for MEDLINE]
16.

Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia.

Martin JL, Pérez V, Sacristán M, Rodríguez-Artalejo F, Martínez C, Alvarez E.

Eur Psychiatry. 2006 Jan;21(1):11-20. Epub 2005 Dec 27. Review.

PMID:
16380237
[PubMed - indexed for MEDLINE]
17.

One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia.

Edwards NC, Pesa J, Meletiche DM, Engelhart L, Thompson AK, Sherr J, Dirani R.

Curr Med Res Opin. 2008 Dec;24(12):3341-55. doi: 10.1185/03007990802490512 . Review.

PMID:
18954497
[PubMed - indexed for MEDLINE]
18.

Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia.

Storosum JG, van Zwieten BJ, Wohlfarth T, de Haan L, Khan A, van den Brink W.

Arch Gen Psychiatry. 2003 Apr;60(4):365-8.

PMID:
12695313
[PubMed - indexed for MEDLINE]
19.

Mortality in elderly dementia patients treated with risperidone.

Haupt M, Cruz-Jentoft A, Jeste D.

J Clin Psychopharmacol. 2006 Dec;26(6):566-70.

PMID:
17110812
[PubMed - indexed for MEDLINE]
20.

Serious cardiovascular events and mortality among patients with schizophrenia.

Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM.

J Nerv Ment Dis. 2004 Jan;192(1):19-27.

PMID:
14718772
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk